Previous studies analyzing the endogenous EPO levels in CKD patients with anemia and in patients with chronic heart failure (CHF) indicate that, in addition to relative EPO deficiency, bone marrow response to endogenous EPO is inhibited in these patients (Van der Putten et al., 2008). This evidence concerns the gene EPO and anemia.